Publication | Open Access

Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viability

Hematological MalignancyMofezolac-derived Cox-1 InhibitorsMedicinePharmacologyTranslational ImpactPharmacotherapyAnti-cancer AgentCancer TreatmentOncologyRadiation OncologyTumor MicroenvironmentCancer ResearchDrug Discovery